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Summary Using a highly sensitive immunofluorometric procedure, we measured the total prostate-specific antigen (PSA) concentration in
632 sera obtained from female blood donors and women with idiopathic hirsutism, breast cancer or benign breast diseases. A total of 50 sera
with total PSA> 15 ng 1-' were fractionated by high-performance liquid chromatography (HPLC) in order to resolve the two immunoreactive
molecular forms, i.e. free PSA (approximately 30 kDa) and PSA bound to a1-antichymotrypsin (PSA-ACT, 100 kDa). We found that breast
cancer patients have presurgical serum total PSA levels similar to those of blood donors. Total serum PSA concentration decreases with age
in women with idiopathic hirsutism, in cancer patients and in patients with benign breast diseases. The major molecular form of PSA in the
serum of all normal and hirsute women (n = 15) is PSA bound to the proteinase inhibitor a,-antichymotrypsin. The major molecular form in
44% of presurgical cancer patient sera-is free PSA. A total of 58% of benign breast disease patients also have in their serum mainly free PSA.
We conclude that about half the patients with breast cancer or benign breast diseases have free PSA as the major molecular form in their
serum, whereas patients without breast pathologies (normal blood donors, idiopathic hirsutism) have PSA bound to a1-antichymotrypsin as
the major molecular form. The ratio of PSA/PSA-ACT may have value as a simple biochemical test for diagnosis of breast pathologies
including breast cancer.
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It is now widely accepted that prostate-specific antigen (PSA) is
present in many non-prostatic tissues and especially in the female
breast (Yu et al, 1994a, 1995a; Levesque et al, 1995; Ferguson et
al, 1996. PSA has also been found in breast cancer cell lines after
hormone stimulation (Yu et al, 1994b, 1995b), in female serum
(Diamandis and Yu, 1995; Giai et al, 1995; Melegos and
Diamandis, 1996) in milk from lactating women (Yu and
Diamandis, 1995a), in breast cyst fluid (Diamandis et al, 1996)
and in amniotic fluid (Yu and Diamandis, 1995b). It has been
found that women whose breast tumours are positive for PSA have
better clinical prognosis (Yu et al, 1995a). In a recent study, we
reported that there are significant differences in the molecular
forms of PSA in serum of women with or without breast cancer
(Melegos and Diamandis, 1996). We found that the predominant
molecular form of PSA in the serum of breast cancer patients is
free PSA (molecular weight 33 kDa), whereas the predominant
PSA form in the serum of normal women is PSA bound to the
proteinase inhibitor ax-antichymotrypsin (PSA-ACT, molecular
weight 100 kDa).
In male serum, the major immunoreactive molecular form is
PSA-ACT; free PSA accounts, on average, for about 18% of total
PSA in benign prostatic hyperplasia (BPH) and is reduced to
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approximately 10% in prostate cancer (PC) patients (Stenman et
al, 1991; Lilja et al, 1994; McCormack et al, 1994). This differ-
ence is used to discriminate between benign prostatic hyper-
plasia(BPH) and prostate cancer (PC) (Leionen et al, 1993;
Luderer et al, 1995). We undertook this study to investigate the
possibility of using the molecular forms of serum PSA in women
for diagnosing breast diseases including breast cancer.
MATERIALS AND METHODS
Serum samples
We examined a total of 632 sera obtained from female blood
donors and women with idiopathic hirsutism, breast cancer or
benign breast diseases (Table 1). Idiopathic hirsutism was included
as a control group of women with increased total serum PSA but
without any breast pathology. Hirsutism was diagnosed based on
published clinical criteria as described elsewhere (Melegos et al,
1997). Serum samples from cancer patients were collected 1-9
days before surgery. Serum samples from patients with benign
breast diseases (BBD) were collected before initiation of therapy.
The vast majority ofBBD patients had fibroadenoma. A total of50
sera containing total PSA > 15 ng 1-1 were selected for HPLC frac-
tionation. All samples were stored at-70°C until use.
High performance liquid chromatography (HPLC)
HPLC was performed with a Hewlett Packard 1050 system. The gel
filtration column used was the TSK-GEL G3000SW 600 x 7.5 mm
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Table 1 Age of patient population
Age (Years)
Patient group Number Range Median Mean > 53 (%)
of sera
All sera
Blood donors 213 20-40 32 32 0%
Idiopathic hirsutism 21 18-42 28 30 0%
Breast cancer 199 31-88 58 55 64%
Benign breast diseases 199 23-79 45 46 17%
Total 632 - - - -
Sera separated by HPLC
Blood donors 10 20-40 27 27 0%
Idiopathic hirsutism 5 22-35 27 27 0%
Breast cancer 16 44-78 63 61 62%
Benign breast diseases 19 28-79 43 45 11%
Total 50 - - - -
incombination with aguardcolumn (Tosoh-Haas, Montgomeryville,
PA, USA). The flow rate was 0.5 ml min-' and the run was isocratic.
The mobile phase was a 0.1 mol 1-' sodium sulphate, 0.1 mol 1-1
sodium phosphate buffer, pH 6.8. The molecular weight standard
solution was from Bio-Rad and was run daily to ensure column
performance. The fraction size collected was 0.5 ml. Before injec-
tion (volumes injected ranged from 50 to 500 ,l, usually 300pl) the
samples were centrifuged at 15 000g for 15 min. Carryover from
previous injections was less than 5%. Serum samples with the
lowest PSA concentration were run first, and after 3-6 runs the
column and the injector were thoroughly cleaned to avoid carryover
in subsequent runs.
PSA immunoassay
PSA was measured with a highly sensitive and specific immuno-
fluorometric procedure. Briefly, the PSA method involves immo-
bilization of a monoclonal antibody to polystyrene microtitre
wells, adding the sample and another biotinylated monoclonal
detection antibody and incubating for 1 h at room temperature.
After washing, the captured PSA is detected by adding strepta-
vidin conjugated to alkaline phosphatase. The activity of alkaline
phosphatase was detected by using the substrate diflunisal phos-
phate. The dephosphorylated form ofthe substrate reacts with Tb3+
and EDTA to form a highly fluorescent complex. Fluoroscence
was quantified using laser excitation and time-resolved fluorom-
etry. The detection limit of this method is 1 ng 1-1. At this PSA
level, precision is < 20%. The performance ofthis assay has been
described in detail (Ferguson et al, 1996). All serum samples were
measured in duplicate.
All values for free and bound PSA were adjusted to the same
volume applied (300 ul-'). A ratio offree to bound PSA was calcu-
lated for all separated samples by dividing the areas of the peaks
representing free PSA and ACT-PSA. A ratio of < 1 means that
ACT-PSA is the dominant molecular form and vice versa.
Statistics
We analysed the correlation of demographic, clinical and patho-
logical variables with total, bound and free PSA and with the ratio
of free to bound PSA. In addition to the analysis of all patients
Table 2 Distribution of total PSA among the various groups of patients
Percentile of total PSA (ng 1-')
Patient group Na 0 25 50 75 100
Blood donors 213 0 0.4 2.0 4.6 68
Idiopathic hirsutism 21 0 2.1 3.6 11 575
Breast cancer 199 0 0.6 1.8 4.4 366
Benign breast diseases 199 0 1.3 3.2 7.5 55 000
aNumber of sera.
together, analyses were performed separately for subgroups of
patients. Relapse and death were not used as classification parame-
ters because ofthe short follow-up (< 1 year) ofthese patients and
the low number ofevents.
The non-parametric unpaired two-tailed Mann-Whitney test
was used for median comparison between groups. Chi-square was
used for analysis of contingency tables. A P-value of < 0.05 was
considered to be significant. When the sample size was relatively
small, the Fisher exact test was used to calculate the differences
between groups in contingency tables. Pearson or Spearman corre-
lation coefficients were calculated as necessary. Logarithmic
transformation was used forthe PSA values in some cases, as indi-
cated in the text.
RESULTS
Total PSA in female serum
Only 1.5% ofthe normal women had a total PSA level > 30 ng 1-'.
The highest percentage ofPSA values over 30 ng 1- was observed
in hirsute women (19.5%), followed by women with benign
breast diseases (7%) and women with breast cancer (6.5%). The
percentage of normal women with PSA > 30 ng 1-1 was signifi-
cantly lower than the percentage ofcancer patients or women with
benign breast diseases or hirsutism (P < 0.05). The group of
hirsute women included a significantly higher percentage of
subjects with a total PSA > 30 ng 1-1 than did the normal and
cancer groups (P < 0.05).
The total PSA distributions in all patient groups were non-
Gaussian and positively skewed. We have thus used only non-
parametric statistics for further data analysis. The percentile
distribution of total PSA among the various patient groups is
shown in Table 2. For normal and breast cancer patients the total
PSA medians were not different (2.0 ng 1- and 1.8 ng 1-' respec-
tively). Hirsute women (n = 21) had a significantly higher total
PSA median than normal women or cancer patients (P < 0.005).
Additionally, women with benign breast diseases had a signifi-
cantly higher total PSA median than normal women or cancer
patients (P < 0.001). The medians of total PSA of women with
benign breast diseases and hirsute women were not statistically
different.
Clinical and pathological variables of patients with
cancer
In Table 1, we list the age distributions of all patients. In Table 3,
we present the clinicopathological data of all cancer patients as
well as those for whom we performed the HPLC separation of
PSA subfractions.
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Table 3 Distribution of clinicopathological data of cancer patients
No HPLC separation (n = 183) HPLC separation (n = 16)
(Per cent of patients) (Per cent of patients)
Age
>53 56 64
Menopause
Yes 75 73
Children
<2 83 56
Breast feeding
Yes 61 64
Time point of sample
collection before surgery
> 1 day 43 55
Tumour size
< 15 mm 47 45
Clinical stage
0 10 0
44 64
11 42 36
III 4 0
Nodal involvement
Yes 29 9
Histological type
Ductal 52 36
Others 38 27
Ductal in situ 11 36
Histological grade
1 25 16
2 52 33
3 22 50
Oestrogen receptor positive
Yes 71 89
Progesterone receptor
positive
Yes 53 75
Adjuvant treatment
None 24 27
Tamoxifen 56 72
Chemotherapy 20 0
Total mastectomy
Yes 51 54
Correlation of clinical data with total PSA
We have examined the effect of age on total PSA using Spearman
or Pearson correlation (logarithmically transformed PSA values in
the Pearson correlation). Spearman analysis did notreveal a signif-
icant correlation between age and total PSA in any of the patient
groups (data not shown). A negative correlation between log (total
PSA) and age was found by Pearson analysis. Results are summa-
rized in Table 4. The correlation was statistically significant in the
groups of hirsute women, women with breast cancer and women
with BBD. The age effect on total PSA is graphically demon-
strated in Figure 1. Statistical analysis using contingency tables
with median age and median total PSA as cut-offlevels confirmed
the data ofthe correlation analysis (data not shown).
We also examined the association between total PSA in serum
and other clinicopathological variables in the group of breast
cancer patients. This analysis confirmed that the serum total PSA
level is not associated with the history of breast feeding, cancer
relapse, tumour size, disease stage, lymph node involvement,
tumour grade, oestrogen or progesterone receptor positivity or
type of surgery (total vs partial mastectomy). Higher total PSA
levels in the serum ofcancer patients were associated with women
Table 4 Effect of patient age on total PSA concentration in seruma
Pearson Correlation
Patient group nb Slope Intercept rc pd
Blood donors 213 - 0.007 0.22 - 0.05 0.490
Idiopathic hirsutism 21 - 0.067 2.88 - 0.49 0.024
Breast cancer 199 - 0.017 1.22 - 0.24 0.0006
,Benign breast diseases 192 - 0.018 1.35 - 0.20 0.005
aPearson correlation between log (PSA) (y) and age (x); bnumber of patients;
cr= Pearson correlation coefficient; dPLvalue for Pearson correlation
coefficient.
who received chemotherapy than in women who received no
therapy or tamoxifen therapy (data not shown). After adjusting for
age, this effect was no longer significant.
The menopausal status of women is strongly associated with
total PSA levels in samples from cancerpatients, similar to data for
age (shown in Table 4). Premenopausal women have higher serum
total PSA levels than post-menopausal women (P = 0.0006).
Further statistical analysis allowed us to summarize the findings
related to total serum PSA as follows: (a) breast cancer patients
have presurgical serum total PSA levels similar to blood donors;
(b) the total PSA level decreases with age in women with idiopathic
hirsutism, in cancer patients and in benign breast disease patients;
(c) patients with ductal carcinoma in situ tend to have higher total
PSA levels than patients with ductal carcinoma or other types of
breast carcinoma; and (d) total serum PSA is not associated with
any other clinicopathological variable shown in Table 3 except for
a weak positive association with the number ofchildren.
Selection of patient sera for HPLC analysis
The molecular forms ofPSA in serum were separated by gel filtra-
tion HPLC. To obtain measurable HPLC fractions for the PSA
assay used (detection limit 1 ng 1-'), the total PSA concentration
must be at least 15 ng 1-'. Provided that enough serum was avail-
able for such analysis, we selected a total of 50 sera (Table 1). No
other criteria were used to select the samples. The distribution of
the total PSA concentration among the samples selected for HPLC
is shown in Figure 2.
Separation of the molecular forms of PSA by HPLC
Using the method described, the two major serum immunoreactive
PSA subfractions can be separated. Examples are given in Figure
3. PSA-ACTelutes first at amolecularweight of90-100 kDa; free
PSA elutes at a molecular weight of approximately 30 kDa. The
area under each peak was used to calculate the relative concentra-
tion ofeach PSA subfraction and the ratio offree PSA/bound PSA
(F/B PSA).
All samples from normal and hirsute women had PSA-ACT as
the major molecular form, even though the amount of the molec-
ular forms were different. Normal women have, in general, very
low levels of serum total PSA. If an HPLC separation is possible,
the level of free PSA was always under 10 ng 1-1 and that of PSA-
ACT under 30 ng 1-'. PSA-ACT was always the predominant
molecular form (Figure 3). The highest ratio offree to bound PSA
observed in normal women was 0.64, with PSA-ACT being the
major molecular form.
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Figure 1 Distribution of total PSA concentration with age in the four patient groups
In hirsute women, bound PSA (PSA-ACT) was always over
10ng1-' andalwaysthepredominantmolecularform. FreePSAlevels
ranged from0 to 22 ng1-'. Consequently, in atotal of 15 patients with
no breast pathology (ten blood donors and five hirsute patients) all
sera have PSA-ACT as thepredominant molecularform (Table5).
We separated, using HPLC, 16 sera obtained presurgically from
breast cancer patients. Nine samples had PSA-ACT as the major
molecular form. The remaining seven had free PSA as the major
molecular form (Table 5 and Figure 4).
In the patient group with benign breast diseases, 8 of 19 patients
had PSA-ACT as the major molecular form and all of them had
free PSA levels < 11 ng 1-1 (Figure 4). Free PSA as the major
molecular form was detected in 11 out of 19 patients. Of note
among four ofthese 11 patients are the levels oftotal PSA, which
ranged between 4800 and 55 000 ng 1-'. These levels are higher
than the levels reported in normal men aged < 50 years (usually
< 2 000 ng 1-l) and are among the highest reported for female sera.
Free PSA
Free PSA is only rarely detectable in serum from normal women.
The median concentration in the separated sera is 1.6 ng 1-1 (Figure
4) and the 95% confidence interval is between 0.7 and 4.5 ng 1-'.
Even though the medians of cancer patients, benign breast disease
(BBD) patients or hirsute women were at least four times higher,
we could not detect any statistically significant difference between
groups, probably because of the small sample size. In cancer
patients as well as BBD patients there were at least three patients
with no detectable free PSA.
Bound PSA
Bound PSA was always detected in the serum of normal women
separated by HPLC. The median was 11 ng1-' (Figure4). The 95%
confidence interval was 6-18 ng 1-l. All othergroups had a median
of at least 2.6 times higher. Bound PSA in BBD patients was not
significantly higher than that measured in normal women because
of the very high standard deviation caused by the four patients
with the extremely high total PSA values. Cancer patients and
hirsute women had significantly higher levels of bound PSA in
comparison with normal women.
Ratio of free to bound PSA
The ratio of free to bound PSA was generally either significantly
less than 1 or higher than 1. The statistical analysis ofthis finding
suggested that there were two patient subgroups (P = 0.028) and
that the molecular forms do not appear at roughly equal levels
except in 3-4 samples out of 50 analysed. The ratio was either
< 0.7 or > 1.5 in most sera (Figure 5).
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Figure 2 Distribution of total PSA concentrations in serum samples
selected for HPLC separation. N = blood donors (n = 10); CA = cancer
patients (n = 16); BBD = benign breast disease patients (n = 19). The
concentration of total PSA in the four samples indicated by a diamond (*)
are 4800, 5700, 8000 and 55 000 ng 1-1; HIR = idiopathic hirsutism (n = 5).
The median of each group is indicated by a horizontal solid line
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Table 5 Ratio of molecular forms of PSA in patient groups separated
by HPLC
Free PSA/PSA-ACT ratio Patients with
ratio > 1
Patient group na Range Median 95% CIb
Blood donors 10 0-0.64 0.20 0.10-0.40 0/10
Idiopathic hirsutism 5 0-0.98 0.084 0.00-0.97 0/5
Breast cancer 16 0-9.60 0.49 0.45-2.96 7/16
Benign breast diseases 19 0-9.51 2.90 2.00-5.70 11/19
an= number of samples; bCl = confidence interval.
The mean and the median of the ratios of normal women were
similar (0.26 and 0.20 respectively). The ratio was never > 1 for
normal as well as hirsute women (Table 5 and Figure 5). The
median ratio for hirsute women was 0.084. Cancer patients had a
median ratio of 0.49. The median ratio of free to bound PSA in
BBD patients was 2.9. This ratio is significantly different from the
F/B PSA ratio ofnormal women (P = 0.04, Figure 5, Table 5).
The number of patients with a ratio of free to bound PSA > 1
was significantly higher in the group of breast cancer and benign
breast disease patients than in blood donors or hirsute women
(Fisher's exact test, P < 0.01).
Our data can be summarized as follows: (a) with the method
used, it is possible to separate clearly free PSA and ACT-bound
PSA; (b) the major serum PSA molecular form in normal women
and hirsute women is PSA-ACT; (c) serum samples from cancer
patients have free PSA as the major molecular form in 44% ofthe
cases; (d) the majority ofBBD patients have free PSA as the major
molecular form in their serum.
Correlation of molecular forms of PSA with clinical data
The distribution ofclinicopathological variables ofcancerpatients
with high (2 15 ng 1-1) and low (< 15 ng [-1) total PSA are shown in
Table 3. The group ofpatients separated by HPLC (n = 16) was not
statistically different from the rest ofthe patients (n = 183) in any
parameter except for the number of children (Fisher's exact test;
P = 0.02; Table 3). For patients with benign breast diseases and
high total PSA (n = 19), the distributions of age, number of chil-
dren, breast feeding and menopausal status were similar (± 5%) to
the whole patientpool (n = 180, data not shown).
*C
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Figure 3 Examples of separation of serum PSA by HPLC and assay of the fractions by the time resolved immunofluorimetric procedure. The serum of the
hirsute patient (A) contains mostly PSA-ACT; the serum of the cancer (B) and benign breast disease (C) patient contains mostly free PSA
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Figure 4 Distribution of free PSA concentration (A) and bound PSA concentration (B) in serum samples subjected to HPLC separation. N = blood donors
(n = 10); CA = cancer patients (n = 16); BBD = benign breast disease patients (n = 19); HIR = idiopathic hirsutism (n = 5). Horizontal solid lines indicate
medians. (A) The concentration of free PSA in samples indicated by a diamond (*) are between 4000 and 8000 ng 1-' and the sample indicated by the star is
40 000 ng l-1. (B) The concentration of bound PSA in the sample indicated by a diamond (*) is 11 157 ng 1-'
Out of all the possible associations of total PSA, free PSA,
bound PSA (PSA-ACT) and ratio of free/bound PSA, we will
highlight a few that are statistically significant.
a. We identified a negative correlation between bound PSA and
age in cancer patient sera (Pearson correlation r = -0.53,
P = 0.04, n = 16 samples). The decrease ofbound PSA with
increasing age is in accord with our finding ofdecreasing total
PSA in the whole population ofcancer patient sera with age
(n = 199; Figure 1). Similar data were obtained for bound PSA
vs age using chi-square analysis. Women over the age of53
years have lower bound PSA in their presurgical serum
(P = 0.04).
b. Serum PSA ratio > 1 occurred more frequently in women with
cancer who had two children or fewer (P = 0.03, n = 16).
c. Total PSA as well as bound PSA in cancer patients (n = 16)
correlated weakly with the number ofchildren. This confirms
data already described for all patients, suggesting that more
children are associated with higher serum total PSA.
d. In cancer patient sera, we found a trend for ductal carcinoma
to be associated with F/B PSA ratio of< 1 (median 0.024) and
for ductal carcinoma in situ (DCIS) with a F/B PSA ratio > 1
(median ratio 3.9). This difference was statistically significant
(P = 0.005). We have already mentioned that the total PSA in
serum is higher in DCIS than ductal carcinomas.
e. Patients with poorly differentiated carcinomas (grade 3), have
serum total PSA and free PSA higher than patients with grade
1 or 2 tumours, but the difference did not reach statistical
significance (P = 0.11 for total PSA and 0.06 for free PSA).
f. Patients who received chemotherapy or tamoxifen after
surgery had higher free PSA and higher F/B ratios in serum
than patients who received no treatment (P = 0.05 for tamox-
ifen vs no therapy; P = 0.11 for chemotherapy vs no therapy).
DISCUSSION
Total PSA in male serum is the most useful tumour marker, and its
value as a diagnostic and monitoring tool in prostate cancer is
beyond doubt. Since the discovery that immunoreactive PSA in
serum consists oftwo molecular forms (PSA bound to ac-antichy-
motrypsin and free PSA), efforts have been made to examine ifthe
ratio of these two components has any diagnostic value. It is now
certain that the free PSA/PSA-ACT ratio decreases in prostate
cancer to a degree that may allow better discrimination between
prostate cancer and benign prostatic hyperplasia (Stenman et al,
1991; Leionen et al, 1993; Lilja et al, 1994; McCormack et al,
1994; Luderer et al, 1995). The reason for the decreased ratio is
not well understood, partially because our knowledge on the
nature of free PSA is limited. Most likely, free PSA is a nicked,
inactive form of PSA that cannot bind to ACT (McCormack et al,
1994; Zhang et al, 1995).
Total PSA levels in serum of women are usually unmeasurable
by conventional PSA assays. However, newer, ultrasensitive
assays can detect immunoreactive PSA in many female sera. In
this study, we used the most sensitive assay reported for this
analyte (Ferguson et al, 1996) to determine not only total PSA but
also the molecular forms ofPSA in many female sera from normal
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Figure 5 Distribution of the ratio of free PSA/bound PSA in samples
selected for HPLC separation. N = blood donors (n = 10); CA = cancer
patients (n = 16); BBD = benign breast diseases (n = 19). Horizontal solid
lines indicate medians. Boxes indicate 95% confidence intervals
women, women with idiopathic hirsutism, benign breast diseases
and breast cancer. This study was triggered by our previous
preliminary finding that PSA-ACT predominates in sera from
normal women but free PSA predominates inpresurgical sera from
patients with breast cancer (Melegos and Diamandis, 1996).
In all the patients examined, total serum PSA was found to be
elevated in patients with idiopathic hirsutism, followed by patients
with benign breast diseases. We have reason to believe that the
increased total PSA in patients with idiopathic hirsutism is due to
hyperandrogenism, as we found a significant correlation between
total PSA in these patients and levels of the dihydrotestosterone
metabolite 3a-androstanediol glucuronide (Melegos et al, 1997).
This notion is also supported by the demonstration ofPSA gene up-
regulation by androgens in breast cancer cell lines (Yu et al, 1994b;
Zarghami et al, 1997). We hypothesize that hyperandrogenism
and/or hyperprogesteronism may account for the increased total
serum PSA in women with benign breast disease. Out of all the
samples (N = 632), four sera from patients with BBD had total PSA
between 4800 and 55 000 ng 1-1, higher than the PSA in serum of
normal males age < 50 years. These levels are among the highest
reported for females (Vessella et al, 1992; Giai et al, 1995).
Unfortunately, we do not yet know why this phenomenon occurred
in fourpatients but not in others with the same disease. We speculate
thatthehyperplastic breasttissueproduces high levels ofPSAunder
stimulation by steroid hormones. It is also possible that, in addition
to the increased production, increased leakage of PSA may also
occur in these tissues, a situation analogous to prostate cancer.
Alternatively, aberrant expression of PSA, due to mutations in the
promoterregion ofthis gene may be the cause ofhigh PSA. Clearly,
more work is necessary to understand this phenomenon better.
We have already shown that PSA is produced by normal as well
as hyperplastic and cancerous breast tissue (Yu et al, 1996). We
demonstrated that total PSA levels show a significant decreasing
trend with age, especially in hirsute women, women with benign
breast diseases and women with breast cancer. This finding is in
accord with data of tissue levels ofPSA in breast cancer and PSA
levels in nipple aspirate fluid. We found higher PSA levels in
tumours and nipple aspirate fluids from younger women (Yu et al,
1994a; Sauter et al, 1996). These data suggest that PSA is regu-
lated by ovarian steroids premenopausaly and probably by adrenal
steroids post-menopausaly.
We found higher levels of total PSA in serum of women with
DCIS and cancer patients with more children. The same trends
were observed for PSA subfractions.
Withthe method used, only sera with total PSA > 15 ng 1-' could
be assessed for PSA subfractions. This limited our sample pool
suitable for fractionation by HPLC from 632 to 50 sera.
Remarkable among our findings was the observation that none of
the sera from patients without breast pathology (n = 15; ten from
blood donors; five fromhirsutepatients) hadfree PSA as the major
molecular form. However, 44% of patients with cancer (presur-
gical sera) and 58% of patients with benign breast diseases had
serum free PSA as the major molecular form. These findings
confirm our preliminary observations (Melegos and Diamandis,
1996). These data allow us to speculate thatfree PSA appears to be
abnormally elevated in diseases of the breast, including fibro-
adenomas and cancer. We propose that free PSA or the ratio of
free/bound PSA, in contrast to total PSA, may have potential for
the diagnosis of benign and malignant breast diseases. This issue
should be examined in more detail, and with more patients, when
new methods for free PSA analysis, without the need for HPLC,
emerge as practical tools (Lilja et al, 1991; Cuny et al, 1996).
Clearly, we would need PSA assays that can measure reliably at
least 0.5 ng 1-1 of free or total PSA. Such assays are now being
developed in our laboratory.
The underlying mechanism of free PSA increase in breast
pathologies is unknown. We previously speculated that free PSA
may be a mutant molecule but recent data do not support this
hypothesis (Tsuyuki et al, 1997). Free PSA may be an inactive
proenzyme, secreted by pathological tissue or a nicked form that is
inactivated by an endopeptidase (McCormack et al, 1994; Zhang
et al, 1995).
In conclusion, we have presented evidence for increased F/B
PSA ratios in serum of patients with benign and malignant breast
diseases. Refinements ofthese new findings may lead to the devel-
opment of simple biochemical tests for diagnosis and monitoring
ofbreast diseases including breast cancer.
ABBREVIATIONS
PSA, prostate-specific antigen; ACT, x1-antichymotrypsin;
A2M, a2-macroglobulin; HPLC, high-performance liquid chro-
matography; ER, oestrogen receptor; PR, progesterone receptor;
F/B PSA, free/bound PSA; BPH benign prostatic hyperplasia;
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PC, prostate cancer, DCIS, ductal carcinoma in situ; BBD,
benign breast diseases.
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